Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Another potentially life-saving treatment for hospitalized Covid-19 patients has been discovered by researchers at the University of Oxford University.

Regeneron antibody 'cocktail' can save lives in hospitalized Covid patients, study finds

Regeneron Pharmaceutical Inc.'s (NASDAQ: REGN) COVID-19 monoclonal antibody cocktail reduced the risk of death by 20% in hospitalized COVID-19 patients who have not mounted their own antibody response, a large-scale study in the U.K. published on Wednesday found. What Happened: Regeneron said that the Phase 3 RECOVERY trial met the primary outcome, improving survival in hospitalized COVID-19 patients lacking an immune response to the coronavirus.

Regeneron Antibody Treatment Cuts Risk Of Death In Some Critical COVID-19 Patients, Large-Scale Study Finds

TARRYTOWN, N.Y., June 16, 2021 /PRNewswire/ -- UK RECOVERY investigators found REGEN-COV reduced risk of death by 20% in patients hospitalized with COVID-19 who had not mounted their own immune response (primary outcome for the primary analysis population) First trial to demonstrate that any antibody treatment improved survival in patients hospitalized with COVID-19 Regeneron will share new data with regulatory authorities immediately and request that the U.S. EUA be expanded to include appropriate hospitalized patients Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today welcomed positive results from the largest trial assessing any monoclonal antibody treatment in patients hospitalized with severe COVID-19.

REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2

Twist Bioscience Corp

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it collaborated with Regeneron Genetics Center LLC (RGC), a wholly-owned subsidiary of Regeneron (Nasdaq: REGN), for the production of a custom next-generation sequencing (NGS) population genetics genotyping assay. Arising from a need to incorporate the genetic differences

Twist Bioscience Collaborates with Regeneron for Production of Genotyping by Sequencing Panel to Enable Diverse Genome-wide Screening

They have to do with production -- and delivery to the patient.

2 Reasons Why This FDA Decision Could Add Billions to Regeneron's Revenue

Incyte

REGN vs. INCY: Which Stock Is the Better Value Option?

REGN vs. INCY: Which Stock Should Value Investors Buy Now?

Twitter

U.S. indices at a mixed day of trading Wednesday as investors and traders weighed the U.S. 30-Year Treasury note falling to 2.1483%, the lowest level since March 1. The SPDR S&P 500 ETF Trust (NASDAQ:SPY) finished slightly higher by 0.02% to $422.28

Twitter And Regeneron Lead The SPY In Another Mixed Day Of Trading

Goldman Sachs

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (Transcript)

Chewy

Merck

Blackrock Inc

Campbell Soup

Companies reporting earnings or speaking with investors this week include Chewy, Campbell Soup, Merck, UPS, and Regeneron. Plus, inflation data and sentiment surveys.

Chewy, Regeneron, UPS, Merck, and Other Stocks to Watch This Week

The FDA has authorized a new, lower-dose version of Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 monoclonal antibody cocktail for those with COVID-19 who are at high risk of progressing to hospitalization. The agency updated the Emergency Use Authorization (EUA) for REGEN-COV, lowering the dose to 1,200 mg (600 mg casirivimab and 600 mg imdevimab),

FDA Expands EUA for Lower Dose Subcutaneous Version of Regeneron's COVID-19 Antibody Cocktail

Shares of Regeneron Pharmaceuticals Inc. were up 1.0% in premarket trading on Friday after the company said U.S. regulators had authorized a lower-dose and subcutaneous version of its COVID-19 antibody treatment. The updated emergency-use authorization now says that patients will receive a dose that is half the size of the original dose of the monoclonal antibody.

Regeneron's COVID-19 antibody drug can now be administered subcutaneously

TARRYTOWN, N.Y., June 4, 2021 /PRNewswire/ --  EUA supported by pivotal Phase 3 data showing 1,200 mg dose reduced risk of hospitalization or death by 70% Only antibody therapy currently available in all 50 states, including eight states with high rates of two variants of concern Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) updated the Emergency Use Authorization (EUA) for REGEN-COV™, lowering the dose to 1,200 mg (600 mg casirivimab and 600 mg imdevimab), which is half the dose originally authorized.

FDA Authorizes Lower 1,200 mg Intravenous and Subcutaneous Dose of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail to Treat Patients with COVID-19

Alnylam Pharmaceuticals

Intellia Therapeutics

Novartis

Pfizer

Here's one genetics play that you might want to put on your radar.

This Genetics Stock Could Have a Bright Future

Barrick Gold

Here are two stocks that can simultaneously add wealth to and protect your portfolio.

2 Top Value Stocks to Hedge Against Inflation Woes

Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer Presents at Annual Bernstein Strategic Decisions Conference (Transcript)

Regeneron's performance so far in the year has been good on the back of a solid product portfolio and an incremental contribution from the antibody cocktail.

Regeneron (REGN) Stock Up 3.5% YTD: What's in Store for 2H21?

Regeneron Just Got a COVID-19 Boost

Aptiv Holdings Ltd

Concho Resources

Fiserv

Altria

Parker-Hannifin

Bill Nygren (Trades, Portfolio), manager of the Oakmark Fund, disclosed this week that his firm's top six trades for the first quarter of 2021 included the closure of its positions in Aptiv PLC ( APTV , Financial) and Parker Hannifin Corp. ( PH , Financial), new stakes in Altria Group Inc. ( MO , Financial) and ConocoPhillips ( COP , Financial) and boosts to its holdings in Regeneron Pharmaceuticals Inc. ( REGN , Financial) and Fiserv Inc. ( FISV , Financial).

Bill Nygren's Top 6 Trades in the 1st Quarter

Eli Lilly

The U.S. government said this week it is halting distribution of Eli Lilly & Co.'s COVID-19 antibody treatment in six states due to the growing prevalence of the P.1 and B.1.351 variants there. Lilly's combination therapy of bamlanivimab and etesevimab "are not active against either the P.1 or B.1.351 variants," which were first identified in Brazil and South Africa, respectively, the Assistant Secretary for Preparedness and Response said Wednesday.

U.S. stops distributing Lilly's COVID-19 antibody therapy in six states, instead recommends Regeneron's treatment

CureVac B.V

Repligen

Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.

Novartis (NVS) & Molecular Partners Initiate Study for COVID-19

Disney

Village Super Market

These investments will help you diversify while giving you a good mix of dividends, growth, and stability.

3 Stocks to Build Your Portfolio Around

Sanofi

Regeneron (REGN) and Sanofi's (SNY) Libtayo gets positive CHMP opinion for two additional indications.

Regeneron (REGN)-Sanofi's Libtayo Gets Positive CHMP Opinion

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Libtayo (cemiplimab) as monotherapy in two advanced cancers. The CHMP recommended the approval of Libtayo for the first-line treatment of adults with non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥50% of tumor cells with no EGFR, ALK, or ROS1 aberrations.

Regeneron-Sanofi's Libtayo Scores CHMP's Positive Opinion For Two Advanced Cancer Settings

TARRYTOWN, N.Y. and PARIS, May 24, 2021 /PRNewswire/ -- Libtayo recommended for approval in the first-line treatment of certain patients with advanced non-small cell lung cancer whose tumors have ≥50% PD-L1 expression Libtayo also recommended for approval in patients with advanced basal cell carcinoma who have progressed on or are intolerant to a hedgehog pathway inhibitor CHMP has now issued three positive opinions for Libtayo in advanced cancers Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for Libtayo® (cemiplimab) as monotherapy in two advanced cancers.

News for Regeneron Pharmaceuticals Stock (REGN)